Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's Generics Program Reaches 'Steady State' Milestone

Executive Summary

OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.

You may also be interested in...



Generic Review At US FDA: Record Month Completes Approval Volume Recovery

With 96 full ANDA approvals and 30 tentative approvals, July was the most productive month since GDUFA launched.

Generics Office At US FDA Could Get New Director Before Uhl Departs

Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.

GDUFA II Reviews Start Strong With High First-Cycle Approval Rate

Performance numbers are likely to fluctuate over the course of the program, but the rate of first-cycle approvals during the first month of the new user fee program is more than double the rate during the last year of the old iteration. 

Related Content

Topics

UsernamePublicRestriction

Register

GB002452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel